Following approval from the Republic of the Philippines Securities and Exchange Commission, the company's step-down ...

AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...

Tata Power, Nazara Tech, Lupin, Biocon, JSW Steel, Shilpa Medicare, and Oriental Rail are some other stocks to watch today, ...

Stocks like India Pesticides, HFCL, NDR Auto Components, JSW Steel, GR Infraprojects, Biocon, Oil and Natural Gas Corporation ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...

Topline results were announced from a phase 3 trial evaluating durvalumab in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...

The European stock markets closed mostly lower in Friday trading as The Stoxx Europe 600 was down 0.38%, Germany's DAX tumbled 1.79%, the FTSE 100 in London was off 0.03%, France's CAC 40 dropped 0.94 ...